Sphingolipids and cardiovascular diseases: lipoprotein metabolism, atherosclerosis and cardiomyopathy

XC Jiang, IJ Goldberg, TS Park - Sphingolipids and Metabolic Disease, 2011 - Springer
XC Jiang, IJ Goldberg, TS Park
Sphingolipids and Metabolic Disease, 2011Springer
Heart disease is widely believed to develop from two pathological processes. Circulating
lipoproteins containing the nondegradable lipid, cholesterol, accumulate within the arterial
wall and perhaps are oxidized to more toxic lipids. Both lipid accumulation and vascular
reaction to the lipids lead to the gradual thickening of the vascular wall. A second major
process that in some circumstances is a primary event is the development of a local
inflammatory reaction. This might be a reaction to vessel wall injury that accompanies …
Abstract
Heart disease is widely believed to develop from two pathological processes. Circulating lipoproteins containing the nondegradable lipid, cholesterol, accumulate within the arterial wall and perhaps are oxidized to more toxic lipids. Both lipid accumulation and vascular reaction to the lipids lead to the gradual thickening of the vascular wall. A second major process that in some circumstances is a primary event is the development of a local inflammatory reaction. This might be a reaction to vessel wall injury that accompanies infections, immune disease, and perhaps diabetes and renal failure. In this chapter, we will focus on the relationship between de novo synthesis of sphingolipids and lipid metabolism, atherosclerosis, and cardiomyopathy.
Springer